» Articles » PMID: 27207947

Endothelial Deletion of Protein Tyrosine Phosphatase-1B Protects Against Pressure Overload-induced Heart Failure in Mice

Overview
Journal Cardiovasc Res
Date 2016 May 22
PMID 27207947
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Cardiac angiogenesis is an important determinant of heart failure. We examined the hypothesis that protein tyrosine phosphatase (PTP)-1B, a negative regulator of vascular endothelial growth factor (VEGF) receptor-2 activation, is causally involved in the cardiac microvasculature rarefaction during hypertrophy and that deletion of PTP1B in endothelial cells prevents the development of heart failure.

Methods And Results: Cardiac hypertrophy was induced by transverse aortic constriction (TAC) in mice with endothelial-specific deletion of PTP1B (End.PTP1B-KO) and controls (End.PTP1B-WT). Survival up to 20 weeks after TAC was significantly improved in mice lacking endothelial PTP1B. Serial echocardiography revealed a better systolic pump function, less pronounced cardiac hypertrophy, and left ventricular dilation compared with End.PTP1B-WT controls. Histologically, banded hearts from End.PTP1B-KO mice exhibited increased numbers of PCNA-positive, proliferating endothelial cells resulting in preserved cardiac capillary density and improved perfusion as well as reduced hypoxia, apoptotic cell death, and fibrosis. Increased relative VEGFR2 and ERK1/2 phosphorylation and greater eNOS expression were present in the hearts of End.PTP1B-KO mice. The absence of PTP1B in endothelial cells also promoted neovascularization following peripheral ischaemia, and bone marrow transplantation excluded a major contribution of Tie2-positive haematopoietic cells to the improved angiogenesis in End.PTP1B-KO mice. Increased expression of caveolin-1 as well as reduced NADPH oxidase-4 expression, ROS generation and TGFβ signalling were observed and may have mediated the cardioprotective effects of endothelial PTP1B deletion.

Conclusions: Endothelial PTP1B deletion improves cardiac VEGF signalling and angiogenesis and protects against chronic afterload-induced heart failure. PTP1B may represent a useful target to preserve cardiac function during hypertrophy.

Citing Articles

Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics.

Sun Y, Dinenno F, Tang P, Kontaridis M Front Cardiovasc Med. 2024; 11:1445739.

PMID: 39238503 PMC: 11374623. DOI: 10.3389/fcvm.2024.1445739.


Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway.

Jiao T, Wang Y, Lin X, Song W, Wang L, Rahman T Front Med (Lausanne). 2023; 10:1256156.

PMID: 38020087 PMC: 10667428. DOI: 10.3389/fmed.2023.1256156.


Targeted inhibition of PTPN22 is a novel approach to alleviate osteogenic responses in aortic valve interstitial cells and aortic valve lesions in mice.

Li S, Luo Z, Su S, Wen L, Xian G, Zhao J BMC Med. 2023; 21(1):252.

PMID: 37443055 PMC: 10347738. DOI: 10.1186/s12916-023-02888-6.


A remarkable adaptive paradigm of heart performance and protection emerges in response to marked cardiac-specific overexpression of ADCY8.

Tarasov K, Chakir K, Riordon D, Lyashkov A, Ahmet I, Perino M Elife. 2022; 11.

PMID: 36515265 PMC: 9822292. DOI: 10.7554/eLife.80949.


PTP1B Inhibition Improves Mitochondrial Dynamics to Alleviate Calcific Aortic Valve Disease Via Regulating OPA1 Homeostasis.

Liu F, Chen J, Hu W, Gao C, Zeng Z, Cheng S JACC Basic Transl Sci. 2022; 7(7):697-712.

PMID: 35958694 PMC: 9357565. DOI: 10.1016/j.jacbts.2022.03.002.